Valcárcel David, Martino Rodrigo, Piñana Jose L, Sierra Jorge
Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Curr Opin Oncol. 2009 Jun;21 Suppl 1:S35-7. doi: 10.1097/01.cco.0000357474.66035.9b.
The antineoplastic effect of allogeneic stem cell transplantation after reduced-intensity conditioning (RIC) relies on the graft-versus-tumour (GvT) reaction. GvT is closely linked to the development of graft-versus-host disease (GvHD). The incidence of acute GvHD after RIC seems lower than after myeloablative conditioning (MAC), whereas the incidence of chronic GvHD after RIC seems similar to after MAC. The results of RIC for acute myeloid leukaemia show a non-relapse mortality of approximately 15% at one year, a relapse incidence of approximately 40% after a median of 4-6 months, translating into overall and disease-free survival rates of 40-60%. The factors associated with improved outcome in most studies are the stage of the disease at transplantation, age and the development of chronic GvHD (and thus GvT). In a recent report, chronic GvHD was the most important factor associated with prolonged survival. Future efforts should be directed at aiming to decrease relapse rates. For this purpose, an adequate identification of high-risk patients, close monitoring of minimal residual disease after the procedure, and the use of antineoplastic drugs or immunotherapy may be of help.
减低剂量预处理(RIC)后同种异体干细胞移植的抗肿瘤效应依赖于移植物抗肿瘤(GvT)反应。GvT与移植物抗宿主病(GvHD)的发生密切相关。RIC后急性GvHD的发生率似乎低于清髓性预处理(MAC)后,而RIC后慢性GvHD的发生率似乎与MAC后相似。急性髓系白血病RIC的结果显示,一年时非复发死亡率约为15%,中位4 - 6个月后复发率约为40%,总生存率和无病生存率为40 - 60%。在大多数研究中,与改善预后相关的因素是移植时疾病的分期、年龄以及慢性GvHD(进而GvT)的发生。在最近的一份报告中,慢性GvHD是与延长生存期相关的最重要因素。未来的努力应致力于降低复发率。为此,充分识别高危患者、术后密切监测微小残留病以及使用抗肿瘤药物或免疫治疗可能会有所帮助。